13-year survival comparison of percutaneous and open nephroureterectomy approaches for management of transitional cell carcinoma of renal collecting system: Equivalent outcomes

被引:81
作者
Lee, BR
Jabbour, ME
Marshall, FF
Smith, AD
Jarrett, TW
机构
[1] Johns Hopkins Hosp, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA
[2] Long Isl Jewish Med Ctr, Dept Urol, New Hyde Park, NY 11042 USA
关键词
D O I
10.1089/end.1999.13.289
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and Objective: Transitional cell carcinoma (TCC) of the renal collecting system traditionally has been managed by open nephroureterectomy with en bloc resection of a bladder cuff. However, for a select patient population with a solitary kidney or bilateral disease, the morbidity and mortality associated with chronic renal insufficiency and dialysis is deterring, In these situations, a more conservative approach such as antegrade percutaneous resection should be considered, The long-term disease-free outcome of percutaneous management in comparison with open nephroureterectomy has not been previously reported. We evaluated our experience with two surgical approaches to treat upper tract TCC: percutaneous resection and nephroureterectomy/nephrectomy to assess the clinical efficacy of these surgical modalities, Patients and Methods: We retrospectively identified 162 patients who had clinically localized TCC of the upper urinary tract. Records were reviewed to identify those with 13-year follow-up (N = 110) in respect to tumor grade, stage, disease-free status,length of cancer-specific survival, and overall survival. Statistical analysis of the results of open nephroureterectomy/nephrectomy (N = 60) and percutaneous resection (N = 50) was performed using Kaplan-Meier survival curves and Student's t-test. Results: All patients had disease in clinical stage Ta through T3. During a mean follow-up of 46.6 (range 6-150) months, grade 1 disease demonstrated little invasive potential. Of the disease-specific deaths, 60% (17/26) were of patients with grade 3 lesions, with a mean cancer survival period of 15.2 months after the initial procedure, Disease-specific survival rates after open and percutaneous approaches for grade 2 disease were 53.8 and 53.3 months, respectively (P > 0.05). Conclusions: Tumor grade appeared to be the most important prognostic indicator in patients with renal TCC regardless of the surgical approach. Grade 3 tumors were more aggressive, presenting in an advanced stage with invasion, and recurrences were usually associated with metastasis. In this population, nephroureterectomy is warranted if the patient is a surgical candidate. The percutaneous option for grade 1 or 2 disease may be extended beyond the population with solitary kidneys and a risk of chronic renal failure to be offered to healthy individuals with normal contralateral kidneys who are willing to abide by a strict and lengthy follow-up.
引用
收藏
页码:289 / 294
页数:6
相关论文
共 24 条
[1]  
Blute ML, 1991, CURR PROBL UROL, V1, P4
[2]   Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma [J].
Elliott, DS ;
Blute, ML ;
Patterson, DE ;
Bergstralh, EJ ;
Segura, JW .
UROLOGY, 1996, 47 (06) :819-825
[3]  
Fraley EE, 1978, GENITOURINARY CANC, P134
[4]   5-YEAR SURVIVAL FOR END-STAGE RENAL-DISEASE PATIENTS IN THE UNITED-STATES, EUROPE, AND JAPAN, 1982 TO 1987 [J].
HELD, PJ ;
BRUNNER, F ;
ODAKA, M ;
GARCIA, JR ;
PORT, FK ;
GAYLIN, DS .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1990, 15 (05) :451-457
[5]   MODIFIED NEPHROURETERECTOMY - A RISK OF TUMOR IMPLANTATION [J].
HETHERINGTON, JW ;
EWING, R ;
PHILP, NH .
BRITISH JOURNAL OF UROLOGY, 1986, 58 (04) :368-370
[6]  
HUFFMAN JL, 1988, UROL CLIN N AM, V15, P419
[7]   PERCUTANEOUS MANAGEMENT OF TRANSITIONAL-CELL CARCINOMA OF THE RENAL COLLECTING SYSTEM - 9-YEAR EXPERIENCE [J].
JARRETT, TW ;
SWEETSER, PM ;
WEISS, GH ;
SMITH, AD .
JOURNAL OF UROLOGY, 1995, 154 (05) :1629-1635
[8]  
JARRETT TW, 1966, ATLAS UROL CLIN N AM, V4, P59
[9]   Ureteroscopic treatment and surveillance of upper urinary tract transitional cell carcinoma [J].
Keeley, FX ;
Bibbo, M ;
Bagley, DH .
JOURNAL OF UROLOGY, 1997, 157 (05) :1560-1565
[10]  
Leyh H., 1996, Journal of Urology, V155, p492A